Top 5 Cheap Stocks for April 2026

Hey there, bargain hunter. April has arrived, and the market just handed you a discount rack. Volatility is up, sentiment is shaky, and some genuinely strong businesses are sitting at prices that would have seemed absurd a year ago. That is exactly when The Cheap Investor goes shopping.

This month, we are looking at five names spanning tech, healthcare, telecom, and semiconductors. Each one has a real business, real cash flow, and a valuation that does not require you to believe in miracles. Let us get into it.

The Scoreboard: Where Things Stand

Before we dig into individual names, here is the macro setup that matters for cheap-stock hunters right now.

• The VIX has pushed above 20, signaling elevated investor anxiety and portfolio reshuffling.
• Morgan Stanley's Mike Wilson flagged the S&P 500 could test the 6,300 level by early April — and that kind of pressure creates entry points.
• Morningstar noted that at the start of 2026, stocks were broadly trading 4% below their aggregate fair value estimate, with small-value stocks trading as much as 23% below fair value.
• Bank of America's equity strategist Jill Carey Hall noted that during rising VIX environments, high-quality stocks and cash-returning businesses have historically outperformed.

Translation: the environment is noisy, but the signal is clear. Own quality at a discount. The five names below fit that brief.

1. Micron Technology (MU) — The AI Memory Play Nobody Is Pricing Right

The setup: Micron just posted one of the most impressive earnings reports in its history, and the market responded by sending the stock down nearly 25% over the following two weeks. That is the kind of disconnect that gets the cheap investor's attention.

Micron's fiscal Q2 2026 earnings, released March 18, showed revenue of $23.86 billion — a 196% increase year-over-year. Non-GAAP gross margins hit a record 74.9%, driven by sky-high selling prices for High Bandwidth Memory (HBM). The sell-off was triggered by two things: elevated capital expenditure guidance and a Google research paper suggesting an algorithm (TurboQuant) could theoretically compress AI memory requirements. Whether that risk is real or overblown, it handed bargain hunters a window.

The Data That Matters

• FY2025 revenue: $37.38 billion, up 48.85% year-over-year
• FY2025 earnings: $8.54 billion, up nearly 1,000%
• Forward P/E: ~7x — unusually low for a company with this growth profile in semiconductors
• HBM supply: Fully booked through 2026, with multi-year pricing agreements locked in
• HBM TAM forecast: Growing at 40% CAGR through 2028, expanding from $35 billion to approximately $100 billion
• Q3 guidance: Revenue of $33.5 billion and adjusted EPS of approximately $19.15 — a step-up from Q2's already-record results
• Analyst consensus: 31 analysts, average rating of Strong Buy, 12-month average price target of $452.93

Why it is cheap: Micron is one of only three suppliers of High Bandwidth Memory globally, and it is the only major memory chipmaker headquartered in the United States — a structural advantage in an era of geopolitical supply-chain reshaping. The market still prices it like a cyclical commodity maker. The business is behaving more like a high-margin infrastructure supplier.

Bull / Base / Bear:

• Bull: HBM demand stays tight past 2026 as management projects. Margins expand further. Stock re-rates toward logic semiconductor multiples.
• Base: Steady 30–40% revenue growth. Stock recovers to $350–$400 range as the TurboQuant panic fades.
• Bear: Google's TurboQuant algorithm reduces memory intensity in AI workloads. Memory market returns to cyclical patterns. Margins compress back toward historical averages.

Action plan: Start a half position here. Add on any further weakness toward the $270–$280 range. This is a name for patient holders with a 12–18 month horizon.

2. Adobe (ADBE) — A Decade-Low Valuation on a 90%-Margin Business

The setup: Adobe's stock has dropped roughly 38% over the past year as investors panic over AI competition from Canva, generative image tools, and a rotation away from high-multiple software names. The fear is real. But the business has not broken.

Adobe's fiscal year 2025 revenue totaled $23.8 billion, up 11% year-over-year, with net income of $7.1 billion growing 28%. Gross margins remain near 90%. Annualized Recurring Revenue (ARR) hit $26.06 billion exiting Q1 FY2026, growing 10.9% year-over-year. This is not a company in crisis. It is a company being priced like one.

The Data That Matters

• Trailing P/E: ~14.5x (as of March 31, 2026) — the lowest in a decade, against a 5-year average of 33.45x
• Forward P/E: ~10.5x — 40% below the software industry median of 17.5x
• Revenue growth: 11% year-over-year for FY2025
• Net income: $7.1 billion, up 28%
• Gross margins: ~90%
• ARR: $26.06 billion, growing 10.9% YoY
• 52-week range: $233.16 – $422.95; currently near the low end
• Analyst average price target: $352.63, implying ~46% upside from current levels

Why it is cheap: Adobe trades at a P/E multiple below the S&P 500 median — a first in its modern history as a public company. The subscription model delivers 90%+ customer retention. Its AI tools (Firefly) are being integrated into enterprise workflows, and a new strategic partnership with NVIDIA announced in March 2026 could accelerate adoption. The market is pricing this like a dying software company. The numbers disagree.

Bull / Base / Bear:

• Bull: AI tools drive a new wave of enterprise seat expansion. Multiple re-rates toward 25x forward earnings. Stock doubles from current levels within 2 years.
• Base: Revenue growth stays in the 10–12% range. Stock recovers to the $340–$360 analyst consensus range over 12–18 months.
• Bear: Canva, AI image generators, and open-source tools erode pricing power. Subscription growth decelerates below 8%. Multiple stays compressed at 12–14x.

Action plan: Build a position in two tranches. Buy half now. If the stock tests $220–$230, add the second half. Adobe's subscription model provides downside support that pure-growth software companies lack.

3. Comcast (CMCSA) — A P/E of 5x and a Dividend Yield Above 4%

The setup: Comcast is not a glamorous story. Linear TV is declining. Broadband competition is intensifying. And the market has priced in years of disappointment, pushing the stock down roughly 15% over the past year. But at current levels, you are not paying for a growth story. You are paying for cash flows.

Comcast's 2025 revenue was $123.71 billion with earnings of $20 billion — up 23.51% year-over-year. The cable broadband business remains structurally entrenched, even as fixed-wireless alternatives chip at the edges. The company is expanding its fiber network, growing its Xfinity Mobile wireless business, and investing in streaming via Peacock.

The Data That Matters

• Trailing P/E: ~5.44x — 64% below its own 10-year median of 15.12x
• GF Value (GuruFocus): $41.20 vs. current price ~$29 — trading roughly 29% below estimated fair value
• DCF intrinsic value (Alpha Spread): $55.81 vs. current price ~$29 — undervalued by ~48%
• Dividend yield: ~4.6% at current price
• 2025 earnings: $20 billion, up 23.51%
• EPS: $5.39 trailing
• Analyst consensus: 19 analysts, average Buy rating, 12-month price target of $35.01 — 25.57% upside
• BofA reiterated Buy on March 25, 2026 with a $37 price target

Why it is cheap: Comcast is a textbook value situation. The market is focused on the secular decline of linear TV and the competitive threat from fiber and fixed-wireless broadband. Those are real risks. But the cable network provides a durable competitive advantage in bandwidth delivery, and the stock is pricing in permanent destruction of a business that is still generating $20 billion a year in earnings. That math does not add up at a 5x P/E. You are being paid to wait with a 4.6% dividend yield.

Bull / Base / Bear:

• Bull: Broadband competition stabilizes. Peacock subscriptions grow. Xfinity Mobile gains share. Stock re-rates to 10–12x earnings — a double from current levels.
• Base: Slow growth, steady cash flow, gradual multiple expansion to 7–8x. Total return including dividend reaches 30–40% over 2 years.
• Bear: Fixed-wireless and fiber accelerate subscriber losses. Peacock continues burning cash. Linear TV decline accelerates. Dividend gets trimmed.

Action plan: Buy for income and eventual re-rating. Set a stop in your head at $24 (prior 52-week low). Collect the 4.6% dividend while you wait. This one requires patience, not a catalyst.

4. AbbVie (ABBV) — The Post-Humira Transition Is Working. The Market Has Not Noticed.

The setup: AbbVie's biggest risk — Humira losing exclusivity — already happened. The stock absorbed approximately $16 billion in U.S. Humira revenue erosion and is still standing. The company is now in growth mode on the other side of one of the biggest patent cliff stories in pharma history. Skyrizi and Rinvoq are picking up the slack, and the pipeline is deep.

AbbVie's 2025 revenue totaled $61 billion, up 8.57% year-over-year. For 2026, guidance targets $67 billion in revenue and $14–$15 in adjusted EPS, with operating margins nearing 49%. The company carries roughly a 3% dividend yield and has grown that dividend consistently for years.

The Data That Matters

• 2025 revenue: $61 billion, +8.57% YoY
• 2026 revenue guidance: $67 billion
• 2026 adjusted EPS guidance: $14–$15
• Forward P/E: ~14.3x on forward estimates
• Pipeline: Approximately 90 products, devices, or new indications in development — roughly 60 in mid-to-late stage testing
• PEG ratio: ~0.40 — significantly below 1.0, suggesting strong growth relative to price paid
• Dividend yield: ~3% at current levels
• Market cap: ~$380 billion
• DCF target (TIKR model): $291 vs. current price ~$215 — implying 30%+ total upside with 9.5% annualized return
• Analyst consensus: Buy, average price target $247.06

Why it is cheap: The forward P/E of ~14x does not reflect the quality of the underlying business. AbbVie has a PEG ratio of just 0.40, meaning growth is grossly underpriced relative to the multiple being assigned. Skyrizi and Rinvoq are now growing fast enough to offset Humira entirely, and the pipeline has 90 programs in development. AbbVie is ranked sixth among the world's largest biomedical companies by revenue. You are buying a biopharmaceutical cash machine at a discount to the S&P 500 average P/E.

Bull / Base / Bear:

• Bull: Skyrizi and Rinvoq continue their growth trajectories. Pipeline delivers one or two late-stage approvals ahead of expectations. Stock reaches $270–$290.
• Base: Steady 8–10% revenue growth. Margin expansion continues. Stock drifts toward analyst consensus of $247 over 12 months, plus dividend income.
• Bear: Regulatory setbacks in oncology or immunology pipeline. Competitive pressure from biosimilars or new entrants squeezes margins. Stock retreats toward $185–$195.

Action plan: Buy a full position. The Humira cliff is priced in and the recovery is already underway. Earnings are due April 24, 2026 — consider sizing in before the report. The dividend provides a floor for patient holders.

5. Alphabet (GOOGL) — $127 Billion in Cash and the World's Deepest AI Moat

The setup: Alphabet is not cheap in the way Comcast is cheap. But for a company generating tens of billions in annual free cash flow, running the world's dominant search engine, a fast-growing cloud platform, and building the most comprehensive AI stack of any public company, a forward P/E in the mid-teens is worth a second look.

Alphabet's most recent quarterly revenue hit $113.83 billion, beating estimates, with net income of $34.45 billion. EBITDA margin stands at 38.17%. Google Cloud is growing fast and adding capacity. Waymo is becoming a commercial reality. The company has $127 billion in cash and equivalents against $59 billion in debt — a net cash position that alone is worth nearly $15 per share.

The Data That Matters

• Q4 2025 revenue: $113.83 billion, +18% YoY
• Net income (quarterly): $34.45 billion
• EBITDA margin: 38.17%
• Cash and equivalents: $127 billion
• Debt: $59 billion (Debt-to-Equity: 1.7%)
• Free cash flow margin: ~40.9% over the trailing period
• EPS Q4 beat: $2.82 vs. $2.63 estimated — a 7% upside surprise
• Q1 2026 earnings date: April 28, 2026
• Analyst sentiment: Analysts citing a $400 price target; Needham flagged weakness as a buying opportunity in late March

Why it is cheap: Alphabet is being discounted for three reasons — antitrust risk around Search, AI competition from ChatGPT and others, and geopolitical noise. None of those risks are trivial. But the business is generating $132 billion in annual net income on revenue growing at 18%. You are effectively buying a full-stack AI company — search, cloud, models, infrastructure, and advertising — at a multiple that would barely qualify as premium for a mature industrial. That is the mispricing.

Bull / Base / Bear:

• Bull: Google Cloud grows to 15% of revenue. AI search monetization opens a new advertising tier. Waymo scales commercially. Stock pushes toward $350–$400.
• Base: Steady 15–18% revenue growth. Antitrust risk gets resolved without structural breakup. Stock recovers to $300–$320 range over 12 months.
• Bear: DOJ forces structural separation of Search and Chrome. AI competitors erode search query volume. Ad pricing stalls. Stock tests $230–$250.

Action plan: Scale in ahead of the April 28 earnings report. Buy a starter position now. Alphabet's cash balance and buyback program provide a meaningful floor. This is one of the few mega-caps that genuinely qualifies as undervalued relative to its growth and free cash flow generation.

The Cheap Investor April Scorecard

Track these 10 items to know when your thesis is working — and when it is not.

1. MU forward P/E stays below 10x — if it expands to 12–15x, the re-rating is already underway
2. MU Q3 revenue guidance of $33.5B holds — any cut is the primary downside risk
3. ADBE ARR growth stays above 10% YoY — the line in the sand for the subscription thesis
4. ADBE forward P/E vs. software median — watch for compression below 10x or expansion above 15x
5. CMCSA broadband subscriber count — quarterly net adds are the single most important metric for thesis health
6. ABBV Skyrizi and Rinvoq combined revenue run rate — needs to stay on track to offset Humira erosion
7. ABBV 2026 full-year EPS guidance — April 24 earnings report is the next major checkpoint
8. GOOGL Google Cloud revenue growth rate — needs to stay above 25% to justify the AI premium
9. GOOGL antitrust ruling updates — any structural breakup order is the bear case trigger
10. VIX direction — if volatility subsides back below 18, value rotation accelerates and these names benefit first

Bottom Line

The market does not give away quality for free. But in April 2026, it is getting close.

If Micron's AI memory supercycle is real and not a one-quarter wonder, MU at 7x forward earnings is the steal of the year. If Adobe's subscription model is stickier than the bears believe, ADBE at a decade-low P/E is a patient investor's dream. If Comcast keeps generating $20 billion a year in earnings while the market prices it at 5x, the dividend alone makes it worth holding. If AbbVie's pipeline delivers and the Humira recovery continues on schedule, $215 will look cheap by year end. And if Alphabet's AI stack is as defensible as its financials suggest, you are buying one of the most powerful cash-generating machines on earth at a mid-teens multiple.

Buy in stages. Watch the scorecard. Do not confuse cheap with broken.

— The Cheap Investor